Abstract 159P
Background
To overcome the common Temozolomide (TMZ) resistance in Glioblastoma (GBM), targeting certain receptors such as GPCRs can be of benefit as they are involved in cancer treatment response signalling pathways. One attractive target is KISS1R, activated by Kisspeptin. RNA-Seq of male GBM samples revealed elevated KISS1R expression and low KISS1 expression, suggesting GBM as a paracrine tumour. By re-modulating KISS1R using exogenous kisspeptin (KP-10), we aimed to positively influence the cytotoxic effect of TMZ and investigate the underlying mechanism(s) in KISS1R-expressing GBM cells.
Methods
KISS1R expression was confirmed using RT-PCR. KP-10/TMZ IC50 was determined using MTT cell viability assay and synergistic combinations were analysed using Isobologram analysis with non-constant ratio. Pathway prediction was done using KEGG, Wikipathways and STITCH. Flow cytometry and live-cell imaging identified molecular mechanisms while relevant markers were assessed via JESS simple Westren. LC-MS/MS was used to identify relevant DEPs with Kaplan-Meier survival analysis to identify clinical relevance.
Results
KISS1R expression was confirmed in A-172 (p53 wild-type) and LN-18 (p53 mutant). KP-10/TMZ treatment demonstrated high synergism in both cells. Pathway analysis of KP-10/TMZ predicted interaction at apoptosis, cytoprotective autophagy and DNA damage. This was further confirmed with elevated autophagy marker p62 in A-172, while increased expression of DNA damage and repair markers PARP and γH2AX in LN-18. The proteomic profiles showed DEPs related to RNA splicing, cytoplasmic translation and ER stress in A-172, while negative regulation of mRNA, glycolysis and MHC class 1 protein binding in LN-18. Ten common DEPs impacted GBM patients’ survival.
Conclusions
The response to KP-10/TMZ treatment varied based on the status of p53 of the GBM cell used and commonly impacted DEPs associated with the cytoplasmic translation of proteins and regulation of mRNA, more seen in LN-18 (p53 mutant). This underscores the significance of delving into the concept of dormant cells within a single tumour to correlate the results from the in-vitro GBM model to actual GBM patients.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
JCSMHS, Monash University Seed Grand and Monash Merit scholarship and funding for doctoral research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
25P - Feasibility of digital spatial profiling as a diagnostic: Comparison to immunohistochemistry (IHC)
Presenter: Hannah Hibbs
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Predictive biomarker discovery for ICI treatment response in metastatic MMRd endometrial cancer through deep proteomic profiling of FFPE tissue samples
Presenter: Juan Francisco Grau-Béjar
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Analytical validation of a small amplicon NGS panel for MSI detection
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Clinical significance of TROP2 expression in lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - PTEN/CREBBP/NOTCH1 co-alterations with TP53/RB1 define molecular subtypes associated with primary therapy resistance in small cell lung cancer (SCLC)
Presenter: Louisa Hempel
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Role of suppressor of cytokine signalling 6 (SOCS6) in colorectal cancer pathogenesis: Integrating clinical and molecular perspectives
Presenter: Asma Al- Bahri
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Adult granulosa cell tumours of ovary: Analysis of 227 non-recurrent and recurrent cases
Presenter: Jan Hojný
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Clinical evaluation cancer testis antigen 45 (CT45) expression in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1)
Presenter: David Halafyan
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - A prognostic signature to predict recurrence in patients with residual disease in triple-negative breast cancer: NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract